Mirae Asset Global Investments
ALLO icon

Mirae Asset Global Investments’s Allogene Therapeutics ALLO Stock Holding History

Mirae Asset Global Investments’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.1K Buy
15,437
+3,715
+32% +$8.16K ﹤0.01% 1424
2026
Q1 		$28.6K Buy
11,722
+802
+7% +$1.61K ﹤0.01% 1385
2025
Q4 		$15K Buy
10,920
+2,342
+27% +$3.09K ﹤0.01% 1572
2025
Q3 		$10.6K Buy
8,578
+128
+2% +$153 ﹤0.01% 1571
2025
Q2 		$9.55K Buy
8,450
+1,434
+20% +$1.91K ﹤0.01% 1498
2025
Q1 		$10.9K Buy
7,016
+29
+0.4% +$55 ﹤0.01% 1457
2024
Q4 		$15.3K Sell
6,987
-576
-8% -$1.42K ﹤0.01% 1458
2024
Q3 		$22K Buy
7,563
+1,330
+21% +$3.55K ﹤0.01% 1418
2024
Q2 		$15.2K Sell
6,233
-355,680
-98% -$1.05M ﹤0.01% 1423
2024
Q1 		$1.77M Buy
361,913
+166,433
+85% +$694K ﹤0.01% 1260
2023
Q4 		$627K Sell
195,480
-233,013
-54% -$661K ﹤0.01% 1858
2023
Q3 		$1.36M Buy
428,493
+32,770
+8% +$144K ﹤0.01% 1377
2023
Q2 		$1.96M Buy
395,723
+30,749
+8% +$166K ﹤0.01% 1226
2023
Q1 		$1.8M Buy
364,974
+28,305
+8% +$182K ﹤0.01% 1264
2022
Q4 		$2.12M Sell
336,669
-48,592
-13% -$450K 0.01% 1115
2022
Q3 		$4.16M Buy
385,261
+59,065
+18% +$803K 0.01% 870
2022
Q2 		$3.72M Buy
326,196
+112,565
+53% +$999K 0.01% 929
2022
Q1 		$1.95M Sell
213,631
-38,829
-15% -$404K ﹤0.01% 1162
2021
Q4 		$3.77M Buy
252,460
+36,378
+17% +$642K 0.01% 958
2021
Q3 		$5.55M Buy
216,082
+42,628
+25% +$1.01M 0.01% 817
2021
Q2 		$4.52M Buy
173,454
+17,401
+11% +$496K 0.01% 840
2021
Q1 		$5.51M Buy
156,053
+70,127
+82% +$2.37M 0.02% 714
2020
Q4 		$2.17M Buy
85,926
+34,517
+67% +$1.13M 0.01% 894
2020
Q3 		$1.94M Buy
51,409
+16,121
+46% +$608K 0.01% 787
2020
Q2 		$1.51M Buy
+35,288
New +$1.28M 0.01% 774

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Mirae Asset Global Investments's ALLO Position: Q2 2026 in Review

Mirae Asset Global Investments increased its Allogene Therapeutics (ALLO) stake by 32% in Q2 2026, buying an estimated $8.16K and bringing the position to 15,437 shares worth $32.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1424.

Mirae Asset Global Investments first reported a position in ALLO in Q2 2020 and has held it in 25 quarters since. The position peaked at $5.55M in Q3 2021. 71 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Mirae Asset Global Investments held 15,437 shares of Allogene Therapeutics worth $32.1K as of Q2 2026.
  • Mirae Asset Global Investments bought 3,715 Allogene Therapeutics shares in Q2 2026, an estimated $8.16K.
  • Allogene Therapeutics made up ﹤0.01% of Mirae Asset Global Investments's portfolio in Q2 2026, its #1424 holding.
  • Mirae Asset Global Investments first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Mirae Asset Global Investments's Allogene Therapeutics position peaked at $5.55M in Q3 2021.
  • 71 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Mirae Asset Global Investments's 13F filing for Q2 2026, filed 22 Jul 2026.